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ABSTRACT10
Pharmacological treatment of several diseases, such as attention deficit hyperactivity disorder
(ADHD), presents marked variability in efficiency and its adverse effects. The genotyping of
specific single nucleotide polymorphisms (SNPs) can support the prediction of responses to
drugs and the genetic risk of presenting comorbidities associated with ADHD. This study
presents two rapid and affordable microarray-based strategies to discriminate three clinically15
important SNPs in genes ADRA2A, SL6CA2, and OPRM1 (rs1800544, rs5569, and rs1799971,
respectively). These approaches are allele-specific oligonucleotide hybridization (ASO), and a
combination of allele-specific amplification (ASA) and solid-phase hybridization. Buccal swab
and blood samples taken from ADHD patients and controls were analyzed by ASO, ASA and a
gold-reference method. The results indicated that ASA is superior in genotyping capability and20
analytical performance.





Pharmacogenetic genotyping easy-going tool
Microarray assay for doctor office applications
Screening of SNP related to a psychiatric disorder on polymer chip30
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INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD), a neurodevelopmental disorder, is
characterized by inattention, hyperactivity and impulsive behavior. This disease is a highly
prevalent childhood-onset neuropsychiatric condition (about 5% in schoolchildren), and is also35
detected in adults [1,2]. One major clinical concern is choice of medication because therapeutic
effectiveness and severe adverse events during treatment vary from patient to patient. In recent
years, pharmagenomics has become a consolidated discipline. It informs physicians about
molecular subtypes of diseases and which drug is more likely to effectively manage the disease
[3,4]. Single nucleotide polymorphisms (SNPs) have been proposed as markers to identify the40
loci associated with complex diseases and their therapeutic treatment [5]. To date,
pharmacogenetic research into ADHD has focused mainly on SNPs related to stimulant drugs
[1,2,6]. In particular, identification in advance of patient-dependent effective drugs (nature and
doses) has been correlated with reduced costs and better quality of life.
Unfortunately, the incorporation of genomic findings into health care systems is limited as the45
cost-effectiveness of analytical methods is the main drawback. In fact, the molecular diagnostics
field is frequently limited to laborious costly methods that require significant infrastructure and
skills, only available for specialized laboratory facilities [7]. The novel generation of diagnostic
tools to detect SNPs from a biologic fluid sample is absolutely necessary to develop genuine
personalized medicine [8]. The challenge will involve genotyping technologies that integrate50
conventional properties; i.e. accuracy, robustness, cost-efficiency or automation, with properties
such as flexibility, portability or simplicity. Yet relatively few SNPs have been identified as
being clinically relevant to treat any given disease. Therefore, the complexity of techniques
could be abridged as low-throughput genotyping approaches would be suitable for most clinical
scenarios.55
Alternative methods to extend SNP genotyping technologies, such as Illumina and Affimetrix
platforms, have been proposed and excellently reviewed [9-12]. Certain solutions lie in
laboratory approaches, designed for the discrimination of only one SNP of a single patient, or
which require equipment that cannot be deployed in resource-limited laboratories.
Consequently, some genotyping platforms are far from being actually integrated into routine60
clinical practice [13].
An advance in SNP genotyping has been made and applied as a pharmacogenetic tool in ADHD
treatment in decentralized medical centers. The system is based on microarray assays,
performed on polycarbonate chips, and on the later colorimetric detection by a biorecognition
process. The use of polymeric substrates is a good solution in research [14], but is key for65
commercial purposes. Polycarbonate is an excellent material given its properties: mass
fabrication under high quality standards, adaptable fabrication of devices, exceptional optical
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properties, wide chemical reactivity for probe anchoring [15,16]. By including similar steps to
microarray assays performed on glass slides, our methodology uses a fast approach and an
inexpensive non fluorescent scanner. Therefore, this method would be accessible for primary or70
secondary health care scenarios, and is affordable for limited health budgets.
In this study, the discrimination of polymorphisms was achieved by two low-throughput
strategies. First, revised allele-specific oligonucleotide hybridization (ASO) was applied using
specific probes that were immobilized on polycarbonate slides. Second, allele-specific
amplification (ASA) was combined with a hybridization assay as a way to simultaneously detect75
amplified products.
For its use as a pharmacogenetic tool, three polymorphisms were studied. Relevant clinical
evidence has been associated with ADHD drugs, such as methylphenidates and amphetamines,
with two SNPs: rs1800544 in the alpha-2 adrenergic receptors (ADRA2A) gene and rs5569
located in the solute carrier family 6 member 2 (SL6CA2) gene [6,17,18]. Information about80
determining the risk of developing comorbidities associated with ADHD is also in demand [19].
Thus an increased risk for substance abuse has been associated with the genetic variants of
polymorphism rs1799971, located in exon 1 of the mu-opioid receptor (OPRM1) gene. This
method is examined for the resourceful integration of genetic testing into routine clinical
practice and doctor office for ADHD management.85
MATERIAL AND METHODS
Patients. Subjects (n=30) with ADHD symptoms and volunteers were diagnosed by specialist
psychiatrists and recruited for the present study according to ethics and with informed consents.
Buccal swab and blood samples were collected. The reference genotyping method was the90
GoldenGate assay with VeraCode Technology (Illumina), which is a high-throughput platform
that combines primer extension and ligation to generate allele-specific products, followed by
PCR for the amplification and hybridization to codified beads for individual readout.
DNA extraction. Extraction was performed using the PureLink Genomic DNA Mini Kit
(Invitrogen), according to the manufacturer’s instructions. Briefly, in order to prepare lysate95
from blood samples, 200 µL of fresh blood, 20 µL of proteinase K, 20 µL of RNase and 200 µL
of kit buffer were added to a microcentrifuge tube. To prepare the human buccal swab lysate,
brushes were placed inside the tube with 500 µL of PBS, 20 µL of proteinase K, 20 µL of
RNase and 500 µL of kit buffer. After incubation at 55 C for 15 min, 500 µL of 96-100%
ethanol were added to the tube and the lysate was loaded into the column and centrifuged at100
10,000 rpm for 1 minute at room temperature. The flow-through was discarded and the column
was washed twice using 500 µL of wash buffer 1 and 2, respectively. Finally, DNA was eluted
with 50 µL of Tris-HCl, pH 8.6.
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Microarraying. Each mixture of streptavidin (10 mg/L) and biotinylated-surface probe (50 nM)105
in printing buffer (50 mM carbonate buffer, pH 9.6 and 1% glycerol (v/v)) was transferred to the
polycarbonate slide (25 mm×75 mm). To that end, a non contact printer (AD 1500 BioDot Inc.,
CA, USA) was used. The drop volume was 50 nL, and working temperature and relative
humidity were controlled at 25 °C and 90%, respectively. The microarray layout consisted of
five arrays of 6×6 dots (ASO approach), or six arrays of 4×6 dots (ASA approach). Each target110
gene, positive control and negative control (immobilization and hybridization) had four
replicates with a 1-mm track pitch. The design restrictions and oligonucleotides used are
described in the Supplementary Material.
ASO approach. A triplex PCR reaction was carried out in a total volume of 12.5 μl. Each115
reaction mixture contained 1x DNA polymerase buffer with 2 mM of MgCl2 (Biotools), 200 μM
of dNTPs (Thermo Scientific), 20 μM of digoxigenin-11-dUTP (digoxigenin-X-5-aminoallyl-
2’-deoxy-uridine-5’triphosphate, Jena Bioscience), 0.4 μM of each specific primer, 0.5 units of
Taq DNA polymerase (Biotools), and 12.5 ng of the genomic DNA. Cycling conditions were:
initial denaturation at 95 °C for 5 min followed by 40 cycles of denaturation at 95 °C for 30 s,120
primer annealing at 60 °C for 30 s, elongation at 72 °C for 30 s, and a final elongation at 72 °C
for 5 min.
A stock solution of saline sodium citrate buffer (SSC 20) was prepared (NaCl 3 M, sodium
citrate 300 mM, pH 7). Prehybridization was performed by dispensing the prehybridization
solution (SSC 1.5×, formamide 30%, and Denhardt’s solution 2.5×) over microarrays and125
incubating slides at 50C for 30 minutes in a conventional oven. For hybridization, 2 µL of PCR
product were mixed with 38 µL of hybridization solution (SSC 1.5×, formamide 30% and
Denhardt’s solution 2.5×). The solution was denatured by heating at 95 °C for 5 min and
transferred onto the slide surface.
After incubation at 37C for 1 h, slides were gently washed for 1 min with diminishing dilutions130
of SSC (SSC 1×, SSC 0.5×, SSC 0.05×) and finally with water. Subsequently, a 1-mL mix of
1:2500 sheep anti-digoxigenin antibody (Abcam), and 1:300 anti-sheep antibody conjugated to
horseradish peroxidase (Abcam) in phosphate buffered saline solution with  0,05% Tween-20
detergent, was dispensed onto the slide and incubated for 30 min at room temperature in the
dark. After washing, 1 ml of 3,3′,5,5′-tetramethylbenzidine reagent (ep(HS)TMB-mA, SDT,135
Germany) was spread onto the slide surface and incubated for 8 min at room temperature. Then
slides were washed with water and read.
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ASA approach. Two triplex PCR reactions (12.5 L) were performed by changing the forward
primers for the studied polymorphisms. Hence mixture A contained primers with a lower140
melting temperature and mixture B contained those with a higher melting temperature. The
reaction mixture contained 1×DNA polymerase buffer without magnesium, 3 mM of MgCl2,
100 μM of dNTPs, 10 μM of digoxigenin-11-dUTP, 0.3 μM of each specific primer, 0.5 units of
DNA polymerase and 4 ng of genomic DNA. Cycling conditions were: initial denaturation at 95
°C for 5 min followed by 35 cycles of denaturation at 95 °C for 30 s, primer annealing at 64 °C145
(mixture A) and 66 °C (mixture B) for 30 s, elongation at 72 °C for 30 s, and final elongation at
72 °C for 5 min.
The products from both mixtures were hybridized separately in two microarrays on
polycarbonate slides, but contained the same oligonucleotides, called common probes. The
microarray assay was performed as described above, but the pre-hybridization step was not150
required and a less stringent hybridization buffer (SSC 1.5×, formamide25%, and Denhardt’s
solution 2.5×) and soft washing protocol (SSC 0.1× solution and water) were used.
Subsequently, an immunoreaction developed the hybridization products.
Detection. Chips were directly scanned (Epson Perfection 1640SU office scanner), and the155
variation of the reflection properties was measured given the presence of the biorecognition
product. If there was no reaction product, the maximum intensity of the reflected beam was
collected (background signal). If target gene-probe recognition and subsequent solid deposit
formation occurred, the light would strike the product, which would attenuate beam intensity
(spot signal). Then gray-scale images (Tagged Image File Format, color depth 16 bit, scale 0-160
65535) were generated and the optical intensity signals of each spot were quantified using in-
home software. Image processing (feature gridding, addressing, segmentation and quality
assurance) was automatically performed in under 5 min.
Discrimination criteria. The analysis was declared valid if the controls provided correct165
responses, and one or two probes of each SNP provided a signal-to-noise ratio above 5. The
genotype decision rule was constructed based on the responses of specific probes for each
polymorphism. A discrimination index was calculated from the signal of the wild-type (WT)
and mutant (MUT) variants, according to the expression (WT − MUT)/(WT + MUT).
Statistical package Statgraphics Centurion for Windows v.16 was used for the data analysis.170
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RESULTS
Allele-specific oligonucleotide hybridization (ASO approach)
A triplex PCR was run for the simultaneous amplification of all the target polymorphisms175
(rs1800544, rs5569, and rs1799971) using specifically designed primers. The most important
variables were MgCl2 concentration, primer concentrations, number of cycles and annealing
temperature. Under the selected conditions (Table 1), the amplification factor was
(2.40.3)109, as determined by fluorescence measurements.
The critical step was the hybridization of the given products with allele-specific probes wild-180
type and mutant) on polycarbonate slides. The optimization experiments are provided in the
Supporting Material and Table 1 summarizes the best conditions. Figure 1 shows the signal-to-
noise ratios (SNR) recorded by the scanner, which demonstrates the selectivity of the
hybridization pattern. A detectable signal was obtained for the perfect-matched duplexes and a
background response (or approached) was acquired for the non matching probes. Therefore, the185
simultaneous genotyping of three SNPs related to ADHD was possible.
Allele-specific amplification (ASA approach)
Targeted gene regions were simultaneously amplified using allele-specific primers. For this
purpose, two triplex reactions (A and B) were run to obtain specific products for both variants190
of each polymorphism (rs1800544, rs5569, and rs1799971). The nature of the DNA
polymerase, the use of modified primers, and the annealing temperature during thermocycling
were optimized (see the Supplementary Material). Under the selected conditions (Table 1), the
amplification of the DNA template from a homozygous patient with the incorrect primer was
comparable to the negative controls (t-test: p-value >0.05). The amplification factor for the195
correct primer was (1.30.3)109.
The detection of ASA products was achieved with a hybridization assay run on a polycarbonate
slide following a similar protocol to the ASO approach. In this case, the PCR products of
reactions A and B were incubated on two microarrays with a specific immobilized probe per
gene (common probe independently of the genetic variant). The hybridization conditions200
(temperature, time, and buffer composition) were optimized by avoiding cross-reactivity
between different genes. Under the selected experimental conditions (Table 1), the comparison
of the hybridization patterns for both microarrays allowed SNP genotyping (Figure 1). A
heterozygous patient led to effective amplification in both reaction mixtures and, consequently,
to positive hybridization in both microarrays (SNR > 3). Amplification occurred in a single205
reaction mixture for a homozygous patient, with a positive result obtained only in the
corresponding microarray.
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Method features for SNP genotyping
Different experiments were performed to establish the capabilities of both methods (ASO and210
ASA) for the genotyping of the three ADHD-related SNPs. Sensitivity was studied by preparing
heterozygous mixtures with decreasing percentages of mutant-type DNA compared to the wild
type. Mutant DNA was detected up to 4% (ASO) and 2% (ASA), which indicates that the
system was capable of discriminating both genotypes selectively. Equimolar mixtures of
genomic DNA from the WT and MUT homozygous patients were prepared and analyzed. For215
both approaches, microarray intensities were comparable to the heterozygous genotypes for the
three polymorphisms (test t: p>0.1). Intra-day reproducibility and inter-day reproducibility,
expressed as the relative standard deviation of spot intensities for triplicate assays, were lower
than 15% and 22%, respectively.
The analytical performances, shown in Table 2, demonstrated that both developed methods were220
adequate as SNP genotyping tools. In fact, the ASO results showed a notably shorter analysis
time and lower cost compared to other published or commercially available allele-specific
hybridization-based methods [6,9,20]. These platforms need long protocols, e.g. overnight
hybridization incubations, and also expensive detection equipment. The method developed
herein to detect ASA products is much simpler and has a greater multiplexing capability than225
previously reported methods [8,21,22]. In these studies, allele-specific products were detected
by electrophoresis or fluorescent dying (real-time or post-amplification). This is also a simpler
approach than previous methods that use hybridization assays on glass chips as it avoids
chemical activation of the surface, surface blocking and using a fluorescent detector [12].
After comparing both the methods developed herein, we found that most assay performances230
were similar. However, the number of simultaneously analyzed samples was larger in the ASO-
based method, while the amount of DNA template required was smaller or the assay time was
shorter in the ASA-based method. The most marked difference was the efforts made to set-up
the multiplex-assay, particularly detection in a microarray format. The design of
oligonucleotides and hybridization buffer composition were more critical in the ASO approach.235
The intrinsic characteristics of ASA genotyping involved a less difficult process to select
optimal conditions. Hence the capabilities of the ASA-based method seems less limited than the
ASO-based method to extend this genotyping tool to other pharmacogenomic applications.
Analysis of ADHD patients240
The discrimination index was calculated for each studied SNP using the signal-to-noise
responses obtained from the three variants (both homozygous and heterozygous individuals).
Although different human samples brought about slight variations in the concentration of the
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PCR products, and consequently scored different optical intensities, the discrimination index
remained nearly constant for intra-groups (ANOVA test: p-value>0.05). A clear difference was245
found among the three groups, which allowed the unequivocal genotype assignment of the
investigated SNP locus. The heterozygous genotypes produced an intermediate discrimination
factor (between -0.3 and +0.3), whereas the homozygous ones led to discrimination factors
above 0.3 (wild-type) and under -0.3 (mutant), respectively.
The method was applied to identify the three loci related to ADHD drugs (rs1800544, rs5569,250
and rs1799971) in the blinded buccal swab and blood samples. Figure 2 illustrates an example
of the microarray images for two patients with a known genotype. As we can see, positive and
negative controls provided detectable and background responses, respectively. In all cases,
positive optical signals were observed according to the specific polymorphism in the
corresponding probes. Nevertheless, the reported genotyping was based on the discrimination255
factors calculated for each studied SNP, and three populations were perfectly distinguished
(Figure 3).
The accuracy of the genotype calls by the microarray-based methods was verified by analyzing
the same genomic DNA extracts from ADHD patients using the Illumina Goldengate platform
(Supplementary Material). Only five polymorphisms were genotyped erroneously by ASO. The260
coincidence percentages fell between 90 % (rs5569) and 100 % (rs1800544) for the ASO
approach, and were 100 % for the ASA approach. The obtained values were comparable to
other low-throughput simple methods that used a single primer/probe per loci [23,24]. The
reliability of the ASO approach can be enhanced by increasing the number of probes by SNP or
including stem probes [6-9]. The comparison to other performances revealed the potential of the265
technique presented herein. Like other high-throughput platforms, the Goldengate bead-array
technology was able to analyze large numbers of SNPs per patient. However, the time required
to perform the entire automated process takes about 3 days and involves extremely expensive
equipment. In contrast, the developed methods provided genotyping information tailored for the
specific disease, e.g. ADHD, in 3.5 h with equipment that is accessible to, and can be afforded270
by, almost any laboratory (thermocycler, heating block, and an office scanner or optical
microscope).
CONCLUSIONS
The pharmacogenetics applied to personalized medicine aims to identify patterns of genetic275
variations with cost-effective tools. These systems would make diagnoses in decentralized
laboratories, which would streamline management and patient care. This paper addresses this
aim developing two fast simple and cheap genotyping methods. Both are based on a simple
array assay performed on a planar polycarbonate support for so-called individualized therapy in
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ADHD. Although the ASO approach gave adequate results, the ASA approach, based on280
hybridization with a common probe immobilized on a solid support, yielded better results. The
experiments confirmed that the SNP genotyping of ADHD patients, supported by analyzing
their genetic code from biological fluids, is actually possible. Nevertheless the present study
must be considered the initial step to develop integrated cheap devices, such as lab-on-a-chips,
fabricated in plastics and combined with a low-cost detection system.285
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Figure 1. Comparison of microarray-based ASO and ASA approaches. Signal-to-noise ratios
(SNR) recorded in each probe for a patient with genotypes: GC for rs1800544, GG for rs5569,340
and AG for rs1799971. WT: wild-type allele-specific probe. MUT: Mutant allele-specific probe.
Parentheses indicates the allelic nucleotide.
Figure 2. Microarray images obtained for two patients. (a) ASO probes: 1= NC, 2=DPC,
3=HPC, 4=rs5569 (WT), 5=rs1800544 (WT), 6=rs1799971 (WT), 7=rs5569 (MUT),345
8=rs1800544 (MUT), 9=rs1799971 (MUT). (b) ASA probes: 1=NC, 2=DPC, 3=HPC,
4=rs5569, 5=rs1800544, 6=rs1799971. Patient 1 genotypes: AG for rs5569, GC for rs1800544,
and GG for rs1799971; Patient 2 genotypes: AG for rs5569, GG for rs1800544, and AA for
rs1799971. Abbreviations: NC= Negative control; DPC: Development positive control; HPC:
Hybridization positive control; WT: Wild-type allele-specific probe; MUT: Mutant allele-350
specific probe.
Figure 3. Discrimination of population groups based on ASA results. Boxplot of discrimination
index for wild-type homozygous (left), heterozygous (central) and mutant homozygous (right)
patients: (a) rs1800544, (b) rs5569, and (c) rs1799971.355
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